Ajanta Pharma advances 2% after launching generic asthma drug

The pharma company announced the launch of Montelukast Sodium Oral Granules (4mg), a bioequivalent generic version of SINGULAIR Granules, in the US market.

Ajanta Pharma has rallied 2% to Rs.1,361 on BSE. The pharma company has announced the launch of Montelukast Sodium Oral Granules (4mg), a bioequivalent generic version of SINGULAIR Granules, in the US market. Ajanta Pharma offers Montelukast Granules in cartons containing 30 individual sachets.

The scrip opened at Rs. 1366 and has touched a high and low of Rs. 1370 and Rs. 1352 respectively. So far 80,466 (NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 11744.21 crore.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1720 on 12-Aug-2015 and a 52 week low of Rs. 842 on 17-Nov-2014. Last one week high and low of the scrip stood at Rs. 1470 and Rs. 1321.95 respectively.

The promoters holding in the company stood at 73.78 % while Institutions and Non-Institutions held 9.66 % and 16.56 % respectively.

The stock is currently trading above its 100 DMA.